Company intelligence / Profile preview

RABOME

Ownership: Private
Development stage: Other

Overview

Rabome is a Japanese biotechnology company specializing in the discovery and development of therapeutic rabbit monoclonal antibodies. Leveraging its proprietary B-cell cloning technology, the company generates high-affinity and highly specific antibodies against challenging drug targets, including GPCRs and ion channels. Rabome's internal pipeline focuses on oncology and inflammatory diseases, with a lead program targeting Claudin-18.2 for gastric and pancreatic cancers. The company also engages in strategic collaborations with pharmaceutical partners to provide antibody discovery services.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Chugai Pharmaceutical

Beyond the preview

Go deeper on RABOME.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RABOME.